Pasar al contenido principal

LINFOCITOS TRANSFAGOCITICOS COMO SIGUIENTE GENERACION DE INMUNOTERAPIAS ANTITUMORALES

SAF2017-84091-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Predicting MHC I restricted T cell epitopes in mice with NAP-CNB, a novel online tool

  • Wert Carvajal, Carlos
  • Sánchez García, Rubén
  • Macías, José R.
  • Sanz Pamplona, Rebeca
  • Méndez Pérez, Almudena
  • Alemany, Ramon
  • Veiga, Esteban
  • Sánchez Sorzano, Carlos Óscar
  • Muñoz Barrutia, María Arrate
Lack of a dedicated integrated pipeline for neoantigen discovery in mice hinders cancer immunotherapy research. Novel sequential approaches through recurrent neural networks can improve the accuracy of T-cell epitope binding affinity predictions in mice, and a simplified variant selection process can reduce operational requirements. We have developed a web server tool (NAPCNB) for a full and automatic pipeline based on recurrent neural networks, to predict putative neoantigens from tumoral RNA sequencing reads. The developed software can estimate H-2 peptide ligands, with an AUC comparable or superior to state-of-the-art methods, directly from tumor samples. As a proof-of-concept, we used the B16 melanoma model to test the system’s predictive capabilities, and we report its putative neoantigens. NAP-CNB web server is freely available at http:// bioco mp. cnb. csic. es/ Neoan tigen sApp/ with scripts and datasets accessible through the download section., This work was funded by the Spanish Ministry of Economy, Industry and Competitiveness (TEC2016-28052-R, RTC2017-6600-1, SAF2017-84091-R, BFERO2020.04), the Spanish Ministry of Science and Innovation (FPU18/03199, PID2019-109820RB-I00), the “la Caixa” Foundation (LCF/BQ/EU19/11710071), FERO foundation and Centro Superior de Investigaciones Científicas (JAEINT18/EX/0636).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

From cellular microbiology to bacteria-based next generations of cancer immunotherapies

  • Osuna-Pérez, Jesús
  • García‐Ferreras, Raquel
  • Veiga, Esteban
Pioneer work by Prof. Cossart among others, studying the interactions between pathogenic bacteria and host cells (this discipline was termed Cellular Microbiology), was fundamental to determine the bacterial infection processes and to improve our knowledge of different cellular mechanisms. The study of bacteria–host interactions also involves in vivo host immune responses, which can be manipulated by bacteria, being these last potent tools for different immunotherapies. During the last years, tumour immunotherapies, mainly the use of antibodies that target immune checkpoints [checkpoint inhibitors (CPI)], have been a revolution in oncology, allowing the treatment of tumours otherwise with very bad prognosis. In the same direction, bacteria inoculations have been used from long to treat some cancers; for example, non‐muscle‐invasive bladder cancer can be successfully treated with the bacterium Bacillus Calmette Guerin (BCG). More recently, it has been shown that microbiota could determine the success of CPI immunotherapies and intense research is being performed in order to use bacteria as immunotherapy tools due to their ability to activate the immune system. In this context, to expand the knowledge of the bacteria–immune system interactions will be fundamental to improve tumour immunotherapies., This work was supported by the grant SAF2017‐84091‐R from the Spanish Ministry of Science Innovation and Universities. J.O.P. has a fellowship (LCF/BQ/SO16/52270012) from La Caixa and R.G.F. has a fellowship (BES‐2016‐076526) from the Spanish Ministry of Economy Industry and Competitiveness.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bacteria-instructed B cells cross-prime naïve CD8+ T cells triggering effective cytotoxic responses

  • García-Ferreras, Raquel
  • Osuna-Pérez, Jesús
  • Ramírez-Santiago, Guillermo
  • Méndez-Pérez, Almudena
  • Acosta-Moreno, Andrés M.
  • Del Campo, Lara
  • Gómez-Sánchez, María José
  • Iborra Pernichi, Marta
  • Herrero-Fernández, Beatriz
  • González-Granado, Jose M.
  • Sánchez-Madrid, Francisco
  • Carrasco, Yolanda R.
  • Boya, Patricia
  • Martínez-Martín, Nuria
  • Veiga, Esteban
In addition to triggering humoral responses, conventional B cells have been described in vitro to cross-present exogenous antigens activating naïve CD8 T cells. Nevertheless, the way B cells capture these exogenous antigens and the physiological roles of B cell-mediated cross-presentation remain poorly explored. Here, we show that B cells capture bacteria by trans-phagocytosis from previously infected dendritic cells (DC) when they are in close contact. Bacterial encounter “instructs” the B cells to acquire antigen cross-presentation abilities, in a process that involves autophagy. Bacteria-instructed B cells, henceforth referred to as BacB cells, rapidly degrade phagocytosed bacteria, process bacterial antigens and cross-prime naïve CD8 T cells which differentiate into specific cytotoxic cells that efficiently control bacterial infections. Moreover, a proof-of-concept experiment shows that BacB cells that have captured bacteria expressing tumor antigens could be useful as novel cellular immunotherapies against cancer., The research is supported by grants: SAF2017-84091-R, and PID2020-116393RB-I00/AEI/10.13039/501100011033, financed by MCIN,BFERO2020.04, financed by FERO foundation and PI20/0036 from ISCIII. RGF issupported by BES-2016-076526 from the Spanish Ministry of Economy Industry and Competitiveness, JOP is supported by fellowship LCF/BQ/SO16/52270012 fromLa Caixa, BHF is supported by FPU18/00895 and AMP by FPU18/03199 from Ministry of Science, Innovation and Universities. LdC hasbeen supported by Juan de la Cierva grant IJC2018-035386-I and a contractas sociated to SEV-2017-0712. EVC, AMP, AMAM, and NMM belong to the Span-ish National Research Council (CSIC)’s Cancer Hub